Back

Serum Phenylalanine, Myo-inositol, and 1,5-Anhydrohexitol biosignature differentiate neonatal sepsis cases from controls

Ahmed, R.; Sarangi, A.; Debata, P.; Gaind, R.; Kaushal, G.; Gur, R.; Shrivastava, S.; Nirmal, K.; Kaur, R.; Nangia, S.; Kumar, V.; Sankar, M. J.; NANDA, R. K.

2024-03-11 infectious diseases
10.1101/2024.03.07.24303587 medRxiv
Show abstract

A more accurate diagnostic biosignature is crucial for neonatal sepsis. In this report, we identified a serum metabolite signature for diagnosing neonatal sepsis cases using mass spectrometry-based profiling of serum samples from two discovery cohorts (set-I/-II: n=71/269) of sepsis patients (culture positive/negative: CP/CN) and controls (no-sepsis: NS or healthy controls: HC). This signature was validated in both cross-sectional (n=60) and follow-up cohorts (n=100). The six-metabolite signature, which includes 1,5-anhydro-D-sorbitol, lactic acid, malic acid, myo-inositol, phenylalanine, and lysine, can distinguish CP and CN sepsis cases from HC. The deregulated serum metabolites returned to HC levels in neonates after completing antibiotic treatment. Additionally, a metabolic signature of PE (20:4(5Z,8Z,11Z,14Z)/0:0, 12-amino-dodecanoic acid, and 1,5-anhydro-D-sorbitol) identified from a validation set-II (n=100) using LC-MS could differentiate CP and CN groups from NS groups. Translating this serum metabolite signature into a simple, deployable blood test for neonatal sepsis could enable faster and more accurate decision-making.

Matching journals

The top 13 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.